XML 31 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segments
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segments
14.
Segments

The Company has one reportable segment which is drug development. The Company primarily derives revenue from its licensing of developed drugs in difficult-to-treat and drug-resistant infections and manages the business activities on a consolidated basis. The Company’s CODM is the Chief Executive Officer. The CODM assesses performance for the drug development segment and decides how to allocate resources based on consolidated net (loss) income that also is reported on the consolidated statement of operations. The CODM uses budget, forecast, and actual results of the consolidated net (loss) income in deciding what drug development programs to further progress with its existing and planned capital resources. The measure of segment assets is reported on the balance sheet as consolidated assets. The accounting policies of the drug development segment are the same as those described in the summary of significant accounting policies in Note 2.

The drug development segment primarily derives revenues from customers by the out licensing of developed drugs which typically include development and other milestones and royalties. Although all operations are primarily based in the United States, the Company generated the majority of its revenue from the license agreement with GSK located outside of the United States for the years ended December 31, 2024 and 2023. All sales, including sales outside of the United States, are denominated in United States dollars. In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation.

The table below provides information about the Company's drug development segment and includes the reconciliation to consolidated net (loss) income for the years ended December 31, 2024 and 2023, respectively (in thousands).

 

 

2024

 

 

2023

 

Revenue

 

$

3,746

 

 

$

140,141

 

Less:

 

 

 

 

 

 

Clinical expense

 

 

8,085

 

 

 

15,452

 

Preclinical expense

 

 

2,420

 

 

 

1,740

 

Chemistry, manufacturing, and controls

 

 

7,161

 

 

 

3,273

 

Selling, general, and administrative

 

 

14,458

 

 

 

20,920

 

Income tax expense

 

 

151

 

 

 

138

 

Interest expense

 

 

828

 

 

 

3,130

 

Plus:

 

 

 

 

 

 

Interest income

 

 

4,291

 

 

 

3,954

 

Other segment (income) expense (1)

 

 

(3,778

)

 

 

32,401

 

Segment net (loss) income

 

 

(21,288

)

 

 

67,041

 

Reconciliation of segment net (loss) income

 

 

 

 

 

 

Adjustments and reconciling items

 

 

—

 

 

 

—

 

Consolidated net (loss) income

 

$

(21,288

)

 

$

67,041

 
(1)
Other segment (income) expense includes other research and development expense, amortization of debt issuance costs and discount, other income, warrant liabilities fair value adjustment, derivative liability fair value adjustment, and cost of product revenue.